8-K: Henry Schein Q2 Profit Dips, Maintains 2025 Outlook

Henry Schein, Inc. reported a decline in second-quarter 2025 GAAP and non-GAAP diluted EPS and Adjusted EBITDA, but maintained its full-year 2025 financial guidance.

Summary

• Second-quarter 2025 GAAP diluted EPS was $0.70, down from $0.80 in Q2 2024.
• Second-quarter 2025 non-GAAP diluted EPS was $1.10, down from $1.23 in Q2 2024.
• Total net sales for Q2 2025 increased 3.3% to $3.2 billion, reflecting 1.9% internal sales growth, 0.8% from acquisitions, and 0.6% from foreign currency exchange.
• Adjusted EBITDA for Q2 2025 was $256 million, compared to $268 million in Q2 2024.
• Year-to-date 2025 total net sales were $6.4 billion, an increase of 1.6% over the first half of 2024.
• The company maintained its 2025 non-GAAP diluted EPS guidance of $4.80 to $4.94, sales growth of 2% to 4%, and mid-single digit Adjusted EBITDA growth.
• A restructuring plan recorded $23 million in costs during Q2 2025, with expected annual run-rate savings of over $100 million by the end of 2025.
• Approximately 3.7 million shares of common stock were repurchased for $259 million in Q2 2025, including the completion of an Accelerated Stock Repurchase plan in July.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While Q2 profitability metrics (EPS, EBITDA) declined year-over-year, sales growth was positive, and the company maintained its full-year guidance, signaling confidence in a stronger second half. Strategic initiatives with KKR and restructuring efforts are underway to drive future growth and efficiencies. Share repurchases also indicate a commitment to shareholder value. The negatives are acknowledged but appear to be managed with forward-looking strategies.

Positives

• Total net sales increased by 3.3% in Q2 2025 to $3.2 billion, driven by internal growth, acquisitions, and foreign currency exchange.
• Global Medical Distribution sales grew strongly by 6.0% in constant currencies, reflecting increased patient traffic and growth in the home solutions business.
• Global Technology sales increased by 6.6% in constant currencies, driven by strong growth in practice management systems like Dentrix Ascend and Dentally cloud-based solutions.
• The company maintained its full-year 2025 financial guidance, indicating confidence in a stronger second half of the year.
• Strategic initiatives are underway with KKR Capstone and two leading global management consulting firms to enhance distribution gross margins and increase efficiencies, with results expected by early 2026.
• A restructuring plan is expected to generate over $100 million in annual run-rate savings by the end of 2025.
• The company repurchased 3.7 million shares for $259 million in Q2 2025, demonstrating a commitment to returning value to shareholders.

Negatives

• GAAP diluted EPS decreased to $0.70 in Q2 2025 from $0.80 in Q2 2024, a 12.5% decline.
• Non-GAAP diluted EPS decreased to $1.10 in Q2 2025 from $1.23 in Q2 2024, a 10.6% decline.
• Adjusted EBITDA decreased to $256 million in Q2 2025 from $268 million in Q2 2024.
• Lower margins in the U.S. Global Distribution Group were experienced primarily due to lower glove pricing and time-limited targeted sales initiatives.
• Global Dental Distribution merchandise sales decreased by 0.4% in constant currencies, impacted by lower average selling prices in the U.S. and Easter timing internationally.
• U.S. Dental Equipment sales were lower due to a slow-down in orders in May resulting from short-term economic uncertainty related to tariffs, although sales returned to normal by quarter-end.
• Global Value-added Services sales were impacted by a high prior year comparable in the practice transitions business.

Risks

• Dependence on third parties for the manufacture and supply of products and raw materials.
• Challenges in achieving strategic growth objectives, including anticipated results of restructuring and value-optimization initiatives.
• Risks related to the Strategic Partnership Agreement with KKR Hawaii Aggregator L.P. entered into in January 2025.
• Transitions in senior company leadership, including succession planning for the Chief Executive Officer.
• Ability to develop or acquire and maintain and protect new products and services that achieve market acceptance with acceptable margins.
• Transitional challenges associated with acquisitions and joint ventures, including failure to achieve anticipated synergies/benefits.
• Adverse changes in supplier rebates or other purchasing incentives.
• Security risks associated with information systems and technology products and services, such as cyberattacks or other privacy or data security breaches (including the October 2023 incident).
• Effects of a highly competitive and consolidating market, including competition from third-party online commerce sites.
• Political, economic, and regulatory influences on the health care industry.
• Changes to laws and policies governing foreign trade, tariffs, and sanctions, including the current imposition of (and potential for additional) tariffs by the U.S. on numerous countries and retaliatory tariffs.
• Supply chain disruption.
• General global and domestic macro-economic and political conditions, including inflation, deflation, recession, unemployment, consumer confidence, and currency fluctuations.
• Litigation risks and new or unanticipated litigation developments.

Future Outlook

The company maintained its 2025 financial guidance, expecting non-GAAP diluted EPS attributable to Henry Schein, Inc. to be $4.80 to $4.94, reflecting growth of 1% to 4%. Total sales growth is projected to be approximately 2% to 4% over 2024, and Adjusted EBITDA growth is expected to increase mid-single digits compared with 2024. Management anticipates earnings to be weighted towards the second half of the year and expects 2025 to serve as a base year for achieving its long-term goal of high-single digit to low-double digit earnings growth. Strategic projects aimed at enhancing distribution gross margins and increasing efficiencies are expected to start producing results towards the beginning of 2026.

Management Comments

• "We had good sales growth in our Global Distribution Group this quarter while experiencing lower margins in the U.S. versus the prior year primarily resulting from lower glove pricing as well as time-limited targeted sales initiatives."
• "We are pleased with the results from these initiatives and have returned to normal levels of promotional activity."
• "Our Specialty Products and Technology Groups continued to deliver strong results, driven primarily by sales from innovative products and solutions, and cost efficiencies."
• "Our full-year guidance, which we are maintaining, continues to reflect earnings weighted to the second half of the year."
• "We expect 2025 to be the base year from which to grow and achieve our previously provided long-term goal of high-single digit to low-double digit earnings growth."
• "Partnering with KKR Capstone, we have engaged two leading global management consulting firms to support our efforts to enhance distribution gross margins, including accelerating sales of our owned-products portfolio, and to support our ongoing company-wide initiatives to increase efficiencies."
• "We expect these projects, which expand on our BOLD+1 strategy, to start producing results towards the beginning of 2026, and will support our ongoing initiatives to drive superior customer satisfaction and our financial goal of high-single digit to low-double digit earnings growth."

Industry Context

Henry Schein operates as the world's largest provider of healthcare solutions to office-based dental and medical practitioners. The reported results reflect a mixed environment, with strong growth in medical distribution and technology solutions, aligning with broader trends of increased patient traffic to physician offices and adoption of digital practice management systems. However, the dental segment faced headwinds from lower glove pricing and short-term economic uncertainties impacting equipment sales, which could reflect a cautious spending environment among dental practices. The company's focus on enhancing distribution gross margins and increasing efficiencies, supported by external consulting, indicates a proactive response to competitive pressures and a drive for operational excellence within the healthcare distribution sector.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for direct industry standard assessment.
• The decline in U.S. dental merchandise sales due to lower glove pricing suggests a normalization or increased competition in the personal protective equipment market post-pandemic.
• The slowdown in U.S. dental equipment orders in May, attributed to economic uncertainty and tariffs, indicates a sensitivity to macroeconomic factors that could affect capital expenditure across the dental industry.
• Strong growth in Global Medical Distribution and Global Technology segments suggests Henry Schein is performing well in areas benefiting from increased patient visits and digital transformation, potentially outpacing competitors focused solely on traditional distribution.

Legal Proceedings

• Litigation settlements were recorded in Q2 2025 and YTD 2025 for one of the company's businesses.
• Litigation settlements in Q2 2024 and YTD 2024 were related to the October 2023 cyber incident and certain opioid-related lawsuits.

Related Party Transactions

• The company entered into a Strategic Partnership Agreement with KKR Hawaii Aggregator L.P. in January 2025.
• The company sold 3.3 million shares of common stock to KKR for $250 million.

Stakeholder Impact

• Shareholders: Impacted by decreased diluted EPS and Adjusted EBITDA in Q2, but also by share repurchases and maintained full-year guidance, suggesting potential for future recovery and value creation.
• Employees: Affected by restructuring initiatives, which aim to increase efficiencies and may involve workforce adjustments.
• Customers (dental and medical practitioners): Benefit from continued investment in innovative products, solutions, and technology (e.g., cloud-based practice management systems), and potentially from enhanced distribution services.
• Suppliers: Continued partnership and potential for increased sales of owned-products portfolio.
• Creditors: Financial results and maintained guidance provide insight into the company's ability to meet its obligations.

Next Steps

• Continue to implement strategic projects with KKR Capstone and management consulting firms to enhance distribution gross margins and increase efficiencies, with results expected towards the beginning of 2026.
• Complete the current restructuring plan by the end of 2025 to achieve over $100 million in annual run-rate savings.
• Focus on achieving the long-term goal of high-single digit to low-double digit earnings growth, with 2025 serving as a base year.

Key Dates

Recommendation

While Henry Schein reported a decline in Q2 2025 profitability metrics (EPS, EBITDA) compared to the prior year, the company maintained its full-year 2025 guidance, indicating that these results were anticipated and that management expects a stronger second half. Strategic initiatives, including a partnership with KKR and a restructuring plan aimed at significant cost savings, are positive long-term drivers. The share repurchase program also signals a commitment to shareholder value. However, the short-term dip in profitability and specific segment weaknesses (e.g., U.S. dental merchandise, equipment) warrant a cautious stance. For a seasoned investor, the current situation suggests a 'hold' as the company navigates short-term headwinds while executing on long-term growth and efficiency strategies, with potential upside contingent on the successful execution of these initiatives in the latter half of 2025 and into 2026.

Keywords

Healthcare Solutions, Dental, Medical, Distribution, Specialty Products, Technology, Financial Results, Earnings, SEC Filing, HSIC, Henry Schein